CareDx (CDNA) Set to Post Quarterly Earnings on Thursday

CareDx (NASDAQ:CDNA) is expected to announce its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect CareDx to announce earnings of $0.2548 per share and revenue of $121.95 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.14. CareDx had a return on equity of 2.87% and a net margin of 24.23%. The company had revenue of $131.95 million for the quarter, compared to the consensus estimate of $114.05 million. During the same quarter in the prior year, the business posted ($0.16) earnings per share. CareDx’s revenue for the quarter was up 52.2% on a year-over-year basis. On average, analysts expect CareDx to post $0.47 EPS for the current fiscal year and $0.63 EPS for the next fiscal year.

CareDx Price Performance

CareDx stock opened at $70.74 on Thursday. The stock has a market capitalization of $3.66 billion, a PE ratio of 407.06 and a beta of 2.38. CareDx has a 12 month low of $14.03 and a 12 month high of $72.71. The business has a 50 day simple moving average of $56.34 and a 200-day simple moving average of $37.35.

Insider Transactions at CareDx

In other CareDx news, Director Christine Cournoyer sold 16,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $46.94, for a total transaction of $751,040.00. Following the completion of the sale, the director directly owned 42,943 shares in the company, valued at approximately $2,015,744.42. The trade was a 27.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director George Bickerstaff, III sold 20,000 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $46.28, for a total value of $925,600.00. Following the transaction, the director directly owned 134,061 shares of the company’s stock, valued at $6,204,343.08. The trade was a 12.98% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on CDNA shares. BTIG Research increased their target price on CareDx from $60.00 to $74.00 and gave the company a “buy” rating in a research report on Thursday, September 24th. HC Wainwright reissued a “neutral” rating and issued a $46.00 price target on shares of CareDx in a research note on Friday, July 31st. Canaccord Genuity Group boosted their price target on shares of CareDx from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Monday. Craig Hallum raised shares of CareDx from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Monday, August 3rd. Finally, Zacks Research cut shares of CareDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Three equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $57.00.

About CareDx

CareDx, Inc is a healthcare diagnostics company focused on improving the care of organ-transplant patients. The company develops and commercializes noninvasive tests and digital tools intended to help physicians assess transplant-organ health, identify potential rejection, and support long-term patient management.

Its offerings include AlloSure donor-derived cell-free DNA tests for monitoring transplant recipients, AlloMap gene-expression testing for heart-transplant patients, and HeartCare, which combines AlloMap and AlloSure results.